Core Insights - Solid Biosciences has entered into a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences for the use of its proprietary capsid, AAV-SLB101, aimed at enhancing gene therapy development [1][2] Group 1: Agreement Details - The agreement allows Andelyn to utilize AAV-SLB101 in conjunction with its AAV Curator® Platform, which optimizes gene therapy manufacturing processes [2] - Financial terms of the agreement have not been disclosed [2] Group 2: AAV-SLB101 Characteristics - AAV-SLB101 is designed for improved skeletal muscle and cardiac tropism while minimizing liver biodistribution [3][5] - The capsid has shown good tolerability in a Phase 1/2 clinical trial involving 23 pediatric participants, with safety data reported as of October 31, 2025 [3] Group 3: Company Statements - The collaboration is expected to accelerate the development of next-generation gene therapies, enhancing safety and efficacy [4] - Andelyn aims to integrate AAV-SLB101 into its platform to provide advanced gene therapy vectors, potentially leading to faster and more cost-effective development [4] Group 4: Company Background - Solid Biosciences focuses on developing precision genetic medicines for rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy [6][7] - Andelyn Biosciences specializes in the development and production of viral vectors for gene therapy, with extensive experience in clinical batch production [8]